Recombinant protein comprising multi-neutralizing epitopes induced high titer of antibodies against influenza a virus

Immunobiology

Volumn 207, Issue 5, 2003, Pages 305-313

  Li, Hua ^a   Ding, Jian ^a   Chen, Ying Hua ^a  

^a TSINGHUA UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISERUM; EPITOPE; INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; NEUTRALIZING ANTIBODY; RECOMBINANT PROTEIN; SEPHAROSE; VIRUS ANTIBODY;

ANIMAL CELL; ANTIBODY BLOOD LEVEL; ANTIBODY SPECIFICITY; ANTIBODY TITER; ANTIGEN PURIFICATION; ANTIGEN RECOGNITION; ANTIVIRAL ACTIVITY; ARTICLE; CELL STRAIN; CONTROLLED STUDY; DRUG DESIGN; ENZYME LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI; INFLUENZA VIRUS; MOUSE; NONHUMAN; PRIORITY JOURNAL; RABBIT; VIRUS NEUTRALIZATION; VIRUS PARTICLE; VIRUS PLAQUE; VIRUS STRAIN; WESTERN BLOTTING;

EID: 0141962309     PISSN: 01712985     EISSN: None     Source Type: Journal    
DOI: 10.1078/0171-2985-00244     Document Type: Article

References (27)

1. Ada GL and Jones PD. 1986. The immune response to influenza infection. Curr. Top. Microbial. Immunol. 128: 1-54.
2. Chen YH, Xiao Y, Yu TW and MP Dierich. 1999. Epitope-vaccine: A new strategy against HIV-1. Immunol. Today 20: 588-589.
3. Corrigan EM and Clancy RL. 1999. Is there a role for a mucosal influenza vaccine in the elderly? Drugs Aging 15: 169-181.
4. Couch RB, Keitel WA and Cate TR. 1997. Improvement of inactivated influenza virus vaccines. J. Infect. Dis. 176 (Suppl. 1): S38-44.
5. Cox NJ and Subbarao K. 1999. Influenza. Lancet 354: 1277-1282.
6. Ding J, Lu Y and Chen YH. 2000. Candidate multi-epitope vaccines in aluminum adjuvant induce high levels of antibodies with predefined multi-epitope specificity against HIV-1. FEMS Immunol. Med. Mic. 29: 123-127.
7. Jeon SH, Ben-Yedidia T and Arnon R. 2002. Intranasal immunization with synthetic recombinant vaccine containing multiple epitopes of influenza virus. Vaccine 20: 2772-2780.
8. Lambkin R and Dimmock NJ. 1995. All rabbits immunized with type A influenza virions have a serum haemagglutination-inhibition antibody response biased to a single epitope in antigenic site B. J. Gen. Virol. 76: 889-897.
9. Lambkin R and Dimmock NJ. 1996. Longitudinal study of an epitope-biased serum haemagglutination-inhibition antibody response in rabbits immunized with type A influenza virions. Vaccine 14: 212-218.
10. Levi R, Aboud-Pirak E, Leclerc C, Lowell GH and Arnon R. 1995. Intranasal immunization of mice against influenza with synthetic peptides anchored to proteosomes. Vaccine 13: 1353-1359.
11. Levi R and Arnon R. 1996. Synthetic recombinant influenza vaccine induces efficient long-term immunity and cross-strain protection. Vaccine 14: 85-92.
12. Li H, Liu ZQ, Ding J and Chen YH. 2002. Recombinant multi-epitope vaccine induces predefined epitope-specific antibodies against HIV-1. Immunol. Lett. 84: 153-157.
13. Lu Y, Ding J, Liu WL and Chen YH. 2002. A candidate vaccine against influenza virus intensively improved the immunogenicity of a neutralizing epitope. Int. Arch. Allergy Immunol. 127: 245-250.
14. Martin JT. 1997. Development of an adjuvant to enhance the immune response to influenza vaccine in the elderly. Biologicals 25: 209-213.
15. Muller GM, Shapira M and Arnon R. 1982. Anti-influenza response achieved by immunization with a synthetic conjugate. Proc. Natl. Acad. Sci. USA 79: 569-573.
16. Naruse H, Ogasawara K, Takami K, Kajino K, Gotohda T, Itoh Y, Miyazaki T, Good RA and Onoe K. 1994. Analysis of epitopic residues introduced into the hybrid peptide vaccines prepared according to the cassette theory. Vaccine 12: 776-782.
17. Ogasawara K, Naruse H, Itoh Y, Gotohda T, Arikawa J, Kida H, Good RA and Onoe K. 1992. A strategy for making synthetic peptide vaccines. Proc. Natl. Acad. Sci. USA 89: 8995-8999.
18. Rajnavolgyi E. 1992. Synthetic peptides in the search for T- and B-cell epitopes. Immunol. Today 13: 17-19.
19. Shapira M, Jibson M, Muller G and Arnon R. 1984. Immunity and protection against influenza virus by synthetic peptide corresponding to antigenic sites of hemagglutinin. Proc. Natl. Acad. Sci. USA 81: 2461-2465.
20. Simeckova-Rosenberg J, Yun Z, Wyde PR and Atassi MZ. 1995. Protection of mice against lethal viral infection by synthetic peptides corresponding to B-and T-cell recognition sites of influenza A hemagglutinin. Vaccine 13: 927-932.
21. Skehel JJ and Wiley DC. 2002. Influenza haemagglutinin. Vaccine 20 (Suppl.): S51-54.
22. Tian HJ, Xiao Y, Zhu M, Dierich MP and Chen YH. 2001. Induction of monoclonal antibodies with predefined epitope-specificity by epitope-vaccines. Immunol. Lett. 75: 161-162.
23. Virelizier JL. 1975. Host defenses against influenza: the role of anti-hemagglutinin antibody. J. Immunol. 115: 434-439.
24. Wang ML, Skehel JJ and Wiley DC. 1986. Comparative analyses of the specificities of anti-influenza hemagglutinin antibodies in human sera. J. Virol. 57: 124-128.
25. Wiley DC, Wilson IA and Skehel JJ. 1981. Structural identification of the antibody-binding sites of Hong Kong influenza haemagglutinin and their involvement in antigenic variation. Nature 289: 373-378.
26. Wilson IA and Cox NJ. 1990. Structural basis of immune recognition of influenza virus hemagglutinin. Annu. Rev. Immunol. 8: 737-771.
27. Xiao Y, Lu Y and Chen YH. 2001. Epitope-vaccine as a new strategy against HIV-1 mutation. Immunol. Lett. 77(1): 3-6.